Bio-Bridge gets U.S. distribution rights for Xinhua's surgical instruments

By Ted A. Knutson

Washington, Nov. 21 - Bio-Bridge Science, Inc. said it has been granted exclusive distribution rights for all Xinhua Surgical Instruments Co., Ltd. surgical instruments in the United States.

The surgical instruments are subject to Food and Drug Administration approval.

"We believe that our agreement with Xinhua will enable us to create a revenue stream as we develop our vaccine program," Bio-Bridge Science chairman and chief executive officer Liang Qia said in a news release.

Xinhua Surgical Instruments is based in Shandong, China.

Oak Brook, Ill.-based Bio-Bridge Science is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications, including an HIV vaccine.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.